Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06902519 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of GS-0151 in Participants With Rheumatoid Arthritis

StatusActive, Not Recruiting
PhasePhase 1
Started2025-05-14
View on ClinicalTrials.gov ↗

Amendment history

2026-09-02
Study Status, Study Design, Contacts/Locations v9
Enrollment closed, study ongoing
Final enrollment: 65 participants (planned 75)
Enrollment targetestimated 75→confirmed 65
Study sitesdetails revised at 35 of 35 sites
2026-06-08
Study Status, Contacts/Locations v8
Trial sites expanded: 32 → 35 locations
2026-05-08
Study Status, Contacts/Locations v7
Study sitesdetails revised at 1 of 32 sites
2026-01-19
Study Status, Contacts/Locations v6
Study sites30→32
2025-12-22
Study Status, Contacts/Locations v5
Primary completion date2027-01→2027-03
Completion date2027-01→2027-03
Study sites17→30
Show 4 earlier versions
2025-10-16
Study Status, Contacts/Locations v4
Study sites15→17
2025-09-16
Study Status, Contacts/Locations v3
Study sites9→15
2025-08-08
Study Status, Outcome Measures, Contacts/Locations v2
Study sites4→9
Secondary endpointsdetails revised at 1 of 2 entries
2025-06-02
Not Yet Recruiting→Recruiting Study Status, Study Design, Arms and Interventions, Contacts/Locations, References v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2026-12→2027-01
Completion date2026-12→2027-01
Start dateestimated 2025-03→confirmed 2025-05-14
Study sites0→4
Study arms3→6
2025-03-24
Original filing
The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is. This will also assess how the drug is absorbed, modified, distributed and cleared from the body (the pharmacokinetics (PK) of the drug), when given multiple times to participants with rheumatoid arthritis (RA). The primary objectives of this study is to assess the safety and tolerability of multiple ascending doses of GS-0151 in participants with RA and to characterize the PK of GS-0151 following multiple doses of GS-0151 in participants with RA.
Trial Details
NCT Number NCT06902519
Lead Sponsor Gilead Sciences
Conditions Rheumatoid Arthritis
Enrollment 65 participants
Start Date 2025-05-14
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-09-03